STOCK TITAN

Camden National (CAC) director receives 919-share equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Denekas Craig N reported acquisition or exercise transactions in this Form 4 filing.

Camden National Corp director Craig N. Denekas received a grant of 919 shares of common stock. The shares were awarded on June 1, 2026 under the Independent Directors' Equity Compensation Program, which is part of the 2022 Equity and Incentive Plan and Amendment.

The award was an equity compensation grant with no cash price per share and vested immediately on the grant date. Following this grant, Denekas directly holds 15,999 shares of Camden National common stock, reflecting his updated ownership position as a director.

Positive

  • None.

Negative

  • None.
Insider Denekas Craig N
Role null
Type Security Shares Price Value
Grant/Award Common Stock 919 $0.00 --
Holdings After Transaction: Common Stock — 15,999 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares granted 919 shares Common Stock grant on June 1, 2026
Grant price $0.00 per share Equity compensation award, non-cash
Shares held after grant 15,999 shares Direct holdings of Craig N. Denekas after transaction
Transaction code A Grant, award, or other acquisition of Common Stock
Transaction direction acquire Non-derivative acquisition via equity grant
Vesting Immediate vesting Shares vested on grant date under director equity program
Independent Directors' Equity Compensation Program financial
"Shares granted under the Independent Directors' Equity Compensation Program, a component of the 2022 Equity and Incentive Plan"
2022 Equity and Incentive Plan financial
"a component of the 2022 Equity and Incentive Plan and Amendment; therefore, price is N/A"
grant/award acquisition financial
"transaction_action: grant/award acquisition with transaction code A for Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Denekas Craig N

(Last)(First)(Middle)
2 ELM STREET
P.O. BOX 310

(Street)
CAMDEN MAINE 04843

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CAMDEN NATIONAL CORP [ CAC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026A919A$0(1)15,999D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares granted under the Independent Directors' Equity Compensation Program, a component of the 2022 Equity and Incentive Plan and Amendment; therefore, price is N/A. These shares vested immediately on the date of the grant.
Remarks:
Christopher G. Hutchinson, POA06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Camden National (CAC) report for Craig N. Denekas?

Camden National reported that director Craig N. Denekas received a grant of 919 shares of common stock. The award was part of the Independent Directors' Equity Compensation Program and represents stock-based compensation rather than an open-market purchase or sale.

How many Camden National (CAC) shares does Craig N. Denekas hold after this Form 4?

After the June 1, 2026 grant, Craig N. Denekas directly holds 15,999 shares of Camden National common stock. This total reflects his updated ownership position, including the 919 shares awarded under the Independent Directors' Equity Compensation Program.

Was the 919-share Camden National (CAC) award to Craig N. Denekas a market purchase?

No, the 919 shares were not a market purchase. They were granted at a stated price of $0.00 per share as equity compensation under the Independent Directors' Equity Compensation Program, meaning Denekas did not pay cash to acquire these shares.

When did Craig N. Denekas receive the 919-share Camden National (CAC) stock grant?

Craig N. Denekas received the 919-share grant of Camden National common stock on June 1, 2026. According to the disclosure, the shares vested immediately on the grant date, making them fully owned by him on that same day.

What plan governed the 919-share equity grant to Camden National (CAC) director Craig N. Denekas?

The 919-share equity grant was made under the Independent Directors' Equity Compensation Program. This program is described as a component of Camden National's 2022 Equity and Incentive Plan and Amendment, which governs stock-based compensation for independent directors.